Literature DB >> 3279989

Diagnosis of susceptibility to malignant hyperthermia in man.

H Ording1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3279989     DOI： 10.1093/bja/60.3.287

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN： 0007-0912            Impact factor:   9.166


× No keyword cloud information.
  7 in total

1.  Evidence for genetic heterogeneity of malignant hyperthermia susceptibility.

Authors:  T Deufel; A Golla; D Iles; A Meindl; T Meitinger; D Schindelhauer; A DeVries; D Pongratz; D H MacLennan; K J Johnson
Journal:  Am J Hum Genet       Date:  1992-06       Impact factor: 11.025

2.  Ryanodine receptor gene point mutation and malignant hyperthermia susceptibility.

Authors:  I Moroni; E F Gonano; G P Comi; V Tegazzin; A Prelle; A Bordoni; N Bresolin; G Scarlato
Journal:  J Neurol       Date:  1995-02       Impact factor: 4.849

3.  High serum creatine kinase levels associated with cylindrical spirals at muscle biopsy.

Authors:  S Rapuzzi; A Prelle; M Moggio; C Rigoletto; P Ciscato; G Comi; F Francesca; G Scarlato
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

Review 4.  Adverse effects of general anaesthetics.

Authors:  M C Berthoud; C S Reilly
Journal:  Drug Saf       Date:  1992 Nov-Dec       Impact factor: 5.606

5.  Functional analysis of RYR1 variants linked to malignant hyperthermia.

Authors:  Jeremy Stephens; Anja H Schiemann; Cornelia Roesl; Dorota Miller; Sean Massey; Neil Pollock; Terasa Bulger; Kathryn Stowell
Journal:  Temperature (Austin)       Date:  2016-02-26

6.  Functional Characterization of C-terminal Ryanodine Receptor 1 Variants Associated with Central Core Disease or Malignant Hyperthermia.

Authors:  Remai Parker; Anja H Schiemann; Elaine Langton; Terasa Bulger; Neil Pollock; Andrew Bjorksten; Robyn Gillies; David Hutchinson; Richard Roxburgh; Kathryn M Stowell
Journal:  J Neuromuscul Dis       Date:  2017

Review 7.  Genotyping of drug targets: a method to predict adverse drug reactions?

Authors:  Cüneyt Güzey; Olav Spigset
Journal:  Drug Saf       Date:  2002       Impact factor: 5.228
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.